Table 1.
Characteristic | No. of patients | % |
---|---|---|
[Median age (range), years | 70 (27–89)] | |
Sex Male Female |
123 48 |
71.9 28.1 |
Cancer type Head and neck cancer Urothelial cancer Renal cell cancer Gastric cancer Esophageal cancer Malignant pleural mesothelioma MSI-high solid tumors a |
50 42 37 20 10 6 6 |
29.2 24.6 21.6 11.7 5.8 3.5 3.5 |
Histological subtype Squamous cell carcinoma Urothelial carcinoma Clear cell carcinoma Adenocarcinoma Epithelioid mesothelioma Sarcomatoid mesothelioma Adenoid cystic carcinoma Neuroendocrine carcinoma Salivary duct carcinoma Not otherwise specified |
54 42 37 26 3 3 1 1 1 3 |
31.6 24.6 21.6 15.2 1.8 1.8 0.6 0.6 0.6 1.8 |
ECOG performance status 0 1 2 3 4 |
46 100 17 7 1 |
26.9 58.5 9.9 4.1 0.6 |
Number of prior systemic therapies 0 1 ≥2 |
2 112 57 |
1.2 65.5 33.3 |
ICI regimen Nivolumab Pembrolizumab |
121 50 |
70.8 29.2 |
MSI, microsatellite instability; ICI, immune checkpoint inhibitor.
MSI-high solid tumors included colorectal cancer (n = 4), cancer of unknown primary (n = 1), and bile duct cancer (n = 1).